Advertisement

Is Novavax Stock a Buy Now?

Is Novavax Stock a Buy Now?

Novavax (NASDAQ: NVAX) investors are looking at a share price decline of more than 90% over the past 12 months, and the shares are now trading close to their 52-week low. Importantly, Gavi has paid Novavax $700 million in the last two years, and its $350 million payment in 2021 accounted for a large fraction of the biotech's $1.1 billion in total revenue for the year.